Cycle-length evidence
Dulaglutide cycle length: what human studies ran
FDA-approvedAHuman trial evidence
Short answer: Dulaglutide has no "cycle". As an approved drug it is used as its label and a prescriber direct.
Treatment and follow-up in human studies
No human study durations are recorded.
What has not been tested
- On-and-off schedules or breaks between courses.
- Repeated courses and long-term exposure beyond the periods listed.
- Dulaglutide combined with other compounds, unless a study above says so.
Frequently asked questions
Is there an established Dulaglutide cycle length?
No cycle is defined. Dulaglutide is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Dulaglutide?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
References
- TRULICITY (dulaglutide) injection, for subcutaneous use, prescribing information (DailyMed, effective 06/2026) FDA label (DailyMed). 2026
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet. 2019
- Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) Diabetes Care. 2021
- Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes N Engl J Med. 2022
- Drugs@FDA (openFDA) application record BLA125469, TRULICITY U.S. FDA. 2026
- World Anti-Doping Agency Prohibited List 2026 (online version) WADA. 2026